Vikram Boparai, DO
Internal Medicine · Miami Beach, FLNPI 1134748544
Payments from drug & device makers
What this record shows
This record is dominated by education: $1,200 of the $1,312 with a category attached, or 91.5%. Supreme Orthopedic Systems, LLC accounts for 91.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,200 and has fallen 98.4% since, to $19 in 2024.
Across 7 payments — averaging $187.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supreme Orthopedic Systems, LLC$1K
- Bayer$21
- Merck$20
- Exact Sciences$19
- Novartis$19
- Pfizer$17
- plus $16 from 1 others
What the payments were for
- Food & beverage$1129%
- Education$1,20091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supreme Orthopedic Systems, LLC | 1 | $1,200 |
| Bayer | 1 | $21 |
| Merck | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Novartis | 1 | $19 |
| Pfizer | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
How this compares
$1,312 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $8,357 |
| Cefdinir | 34 | $343 |
| Azithromycin | 21 | $86 |
| ClopidogrelClopidogrel Bisulfate | 12 | $33 |
| Furosemide | 13 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $8,35713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami Beach
- Jason ShapiroMiami Beach$69K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.